In line with the above mentioned results, PTPRD/PTPRT mutations were also determined to be an independent pan-cancer predictive factor for patients treated with ICIs (univariate: HR = 0.657, 95% CI: 0.449-0.961, P = 0.030; multivariate: HR = 0.612, 95% CI: 0.417-0.896, P = 0.012) (Supplementary Table 2). Here, PTPRT is linked to cancer.